Posted byOrthoEx Posted in
Posted on Mar 12, 2018

KIRKLAND, QCMarch 8, 2018 /CNW Telbec/ – Ortho Regenerative Technologies Inc. (CSE: ORTH.CN) (“Ortho RTi” or the “Corporation”), an emerging Orthopaedic and Sports Medicine Technology company, today announced it has received a Notice of Allowance from the European Patent Office for European Patent Application Number 10831000.4 entitled, “Novel Forumulation of Physiological Chitosan-Inorganic Salt Solution/Blood Mixtures for Tissue Repair.”

Once the administrative process is complete, the European Patent that issues from this application will provide intellectual property protection for the composition of matter of Ortho RTi’s ‘Ortho-R’ for the biologic repair of tissue.

“This allowance is from the second series of patent applications we have made to cover our propriety biopolymer platform around the globe,” said Ortho RTi’s Executive Chairman and CEO, Dr. Brent Norton.  “As awareness and acceptance of the promise that Ortho-R holds for improving the repair of three distinct joint tissues – the rotator cuff tendons, the meniscus and articular cartilage – it is important to ensure that the potential market opportunities these represent are well protected.  To that end, our expanding intellectual property estate should ensure that our game-changing technology has long-term market exclusivity.”

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair devices to dramatically improve the success rate of sports medicine surgeries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at

Forward-Looking Statements

This news release may contain certain forward-looking statements regarding the Corporation’s expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

SOURCE Ortho Regenerative Technologies Inc.

For further information: Stephen Kilmer, Investor & Media Relations, 647.872.4849,